SapVax is developing a range of peptide-based therapeutic vaccines based on its proprietary platform
The SapVax technology is based on rapid and simple synthetic peptide chemistry, allowing it to be highly versatile and easy to manufacture. The platform is optimized for a range of oncology indications, and it can also be developed for the delivery of neo-antigens and CAR-T therapies.
Our strategy focuses on developing our platform and its first lead constructs, in-house and through strategic partnerships.
SPV401, our lead construct is expected to begin phase I clinical trials in 2020.
Current Development Partners
SapVax has signed an exclusive license agreement for aspects of our self-adjuvanting peptide-based platform from the University of Auckland, New Zealand.
Additional development partners and collaborators include The Harrington Project - including the Harrington Discovery Institute at University Hospitals and BioMotiv, LLC, in addition to Auckland UniServices, and Innovator Capital Limited. Learn more about SapVax’s development partners here.